Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,400.96
(
-0.16%
)
US TECH 100
28,206.80
(
-1.14%
)
Dow Jones
49,760.56
(
0.11%
)
Brent Oil
104.74
(
-0.96%
)
Bitcoin
81,223.93
(
0.91%
)
News Focus
News Focus
Post# of 347009
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (4) Keep Next 10 Report Keyboard Shortcuts
Replies (4) Next 10 Prev Next

biopharm

Send PM Follow Ignore
Followers 84
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

biopharm

Re: biopharm post# 235632

Saturday, 09/26/2015 4:11:24 PM

Saturday, September 26, 2015 4:11:24 PM

Post# of 347009

How did I miss this Gilead and Peregrine ?

Did Peregrine just stepp into a partnership with Gilead right before us not even knowing it? Though the last time we seen this on a smaller scale with Ambit Biosciences they were bought out so lets see what happens....

plain as day it certainly says employment with Peregrine and Gilead beginning back in March of 2015

Experience
Sr. Director Medical Affairs
Peregrine Pharmaceuticals, Inc.
March 2015 – Present (7 months)Tustin, CA

Director Clinical Research-Oncology and Inflammation Therapeutics
Gilead Sciences
July 2012 – Present (3 years 3 months)Foster City, CA

https://www.linkedin.com/pub/lisa-stepp-phd-mba/a/942/345



Wonder who informed Lisa Stepp to update her profile....

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline." -- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Public Reply Private Reply New Post
Keep Last Read
Replies (4) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (4) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote